Struggling With Depression? Learn About A Study Exploring New Options For Adults Living With Treatment-Resistant Depression

S
Susan Conroy, MD PhD

Primary Investigator

Struggling With Depression? Learn About A Study Exploring New Options For Adults Living With Treatment-Resistant Depression
Recruiting
22 years - 70 years
All
Phase N/A
1 participants needed
1 Location

Brief description of study

Still searching for relief from depression? Have you tried multiple treatments for depression without success? You may have another option.

When treatments haven’t worked, research may offer a new path. The Abbott TRANSCEND study is a research study for adults with depression who have not felt better after trying at least four different antidepressant medications. 

The purpose of the study is to learn how safe and effective a treatment called deep brain stimulation (DBS) may be for people with treatment-resistant depression. DBS uses a medical device made by Abbott to deliver gentle electrical signals to specific areas of the brain. This treatment is still being studied and is not yet approved for this use.

You may qualify to join this study if you:

  • Are between the ages of 22 and 70
  • Have been diagnosed with depression and are currently experiencing a depressive episode for at least 12 months
  • Have tried at least 4 different treatments without success
  • Are willing and able to attend regular study visits at the IU Health Neuroscience Center in Indianapolis, IN over the course of 3 years

 

Please visit this link to complete registration to be contacted for this study: https://redcap.link/TRANSCEND

Detailed description of study

If you are eligible and choose to participate, here's what you can expect:

  • You will be randomly assigned, like the flip of a coin, into one of two groups; one group will receive active DBS treatment, and the other group will receive a sham (inactive) treatment (neither you nor the study doctors will know which group you are in during the first part of the study).
  • After 12 months, you will be told which group you were in, and participants who were in the sham group will then receive active DBS treatment.
  • Total study participation lasts 18 months (this includes follow-up visits).
  • All study visits will take place at the IU Health Neuroscience Center (Goodman Hall CRC) in Indianapolis, IN.
  • You will receive financial support to help cover travel costs for study visits, including $125 for follow-up visits.

Please visit this link to complete registration to be contacted for this study: https://redcap.link/TRANSCEND

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Treatment Resistant Depression
  • Age: 22 years - 70 years
  • Gender: All

Inclusion Criteria:

1. Have been diagnosed with depression and currently experiencing a depressive episode for at least 12 months, or have symptoms that continue to come back

2. Open to considering an investigational surgical option for depression treatment

3. Willing to get copies of your records for the last few years from psychiatrist to provide to our team

4. Have tried at least four treatments and not found them helpful, including: 

  • Difference medications like Zoloft, Prozac, Lexapro, Wellbutrin, Paxil, Effexor, Cymbalta, and/or combinations of these with other medications
  • Cognitive behavioral therapy, psychotherapy, or other talk therapies
  • Transcranial magnetic stimulation
  • Electroconvulsive therapy

5. Ability to commit to regular visits for over the course of 3 years

6. Willing to transfer psychiatric medical care to the study psychiatrist for a 12-month period

Exclusion Criteria:

1. Pregnant or those who plan to become pregnant during study

2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol.

3. Current or lifetime history of psychotic features in any Major Depressive Episode.

4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication.

5. Significant acute suicide risk.

6. Diagnosis of Substance Use Disorder or Alcohol Use Disorder without sustained remission (12 months or longer).

7. Current and ongoing use of neurostimulation treatment that may interfere with DBS therapy/system.

8. Treatment with another investigational device or investigational drugs.

Updated on 07 Jan 2026. Study ID: PSYC-ABBOTT-TRANSCEND, 29301

Pre-Screener

Check if you are eligible Enter contact details Select a study center Select best time to contact

If you are interested in participating in this study, please follow this link and complete our survey:

Please visit this link to complete registration to be contacted for this study: https://redcap.link/TRANSCEND


Preview complete

The prescreener preview is complete. You may now close the preview.

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the Study Team